Search Results
Jan 13, 2026, 06:00 ET Maple Leaf Foods Announces 2026 Financial Guidance and Dividend Increase
Operational Guidance HighlightsThe Company expects the following for fiscal 2026:Revenue Growth: Mid-single digit ("MSD") increase in revenue from 2025, driven by the execution of proven growth strategies, including leveraging leadership in Sustainable Meats, investing
More news about: Maple Leaf Foods Inc.
Jan 13, 2026, 06:00 ET Maple Leaf Foods Announces 2026 Financial Guidance and Dividend Increase
Operational Guidance HighlightsThe Company expects the following for fiscal 2026:Revenue Growth: Mid-single digit ("MSD") increase in revenue from 2025, driven by the execution of proven growth strategies, including leveraging leadership in Sustainable Meats, investing
More news about: Maple Leaf Foods Inc.
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.The multi-center Phase
More news about: Phanes Therapeutics, Inc.
Jan 06, 2026, 17:00 ET ProLogium, Kyushu Electric Power and Nakayama Iron Works Join Forces to Pioneer a New Era in Construction Machinery
ProLogium solid-state batteries. The module is also planned for integration into two groundbreaking zero-emission construction machines — the MSD700 and NE100HBJ. This partnership not only establishes a vertically integrated ecosystem spanning from battery cell to end product, but also
More news about: ProLogium
Jan 06, 2026, 17:00 ET ProLogium, Kyushu Electric Power and Nakayama Iron Works Join Forces to Pioneer a New Era in Construction Machinery
ProLogium solid-state batteries. The module is also planned for integration into two groundbreaking zero-emission construction machines — the MSD700 and NE100HBJ. This partnership not only establishes a vertically integrated ecosystem spanning from battery cell to end product, but also
More news about: ProLogium
Jan 06, 2026, 06:50 ET W. L. GORE & ASSOCIATES ÜBERNIMMT CONFORMAL MEDICAL UND BAUT SEINE PRÄSENZ IM BEREICH DER ENDOVASKULÄREN BEHANDLUNGEN AUS
Versicherer. Gore arbeitet mit Klinikern zusammen und verbessert durch diese Zusammenarbeit die Lebensqualität der Menschen. goremedical.comBDT & MSD Partners fungiert als exklusiver Finanzberater und Davis Polk als Rechtsberater von W. L. Gore & Associates. Piper Sandler fungiert als exklusiver
More news about: W. L. GORE & ASSOCIATES
Jan 06, 2026, 01:43 ET W. L. GORE & ASSOCIATES ACHÈTE CONFORMAL MEDICAL ET RENFORCE SA PRÉSENCE DANS LES TRAITEMENTS ENDOVASCULAIRES
bénéficier d'économies durables. Gore est au service des cliniciens et, grâce à cette collaboration, améliore des vies. goremedical.comBDT & MSD Partners agit en tant que conseiller financier exclusif et Davis Polk en tant que conseiller juridique de W. L. Gore & Associates. Piper Sandler
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 13:04 ET W. L. GORE & ASSOCIATES ADQUIERE CONFORMAL MEDICAL, AMPLIANDO SU PRESENCIA EN TRATAMIENTOS ENDOVASCULARES
hospitales y aseguradoras. Gore colabora con los profesionales clínicos y, a través de esta colaboración, mejora vidas. goremedical.comBDT & MSD Partners actúa como asesor financiero exclusivo y Davis Polk como asesor legal de W. L. Gore & Associates. Piper Sandler actúa como asesor financiero
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 09:37 ET W. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTS
hospitals and insurers. Gore is joined in service with clinicians and through this collaboration is improving lives. goremedical.comBDT & MSD Partners is acting as exclusive financial advisor and Davis Polk is serving as legal counsel to W. L. Gore & Associates. Piper Sandler is acting
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 09:18 ET W. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTS
hospitals and insurers. Gore is joined in service with clinicians and through this collaboration is improving lives. goremedical.comBDT & MSD Partners is acting as exclusive financial advisor and Davis Polk is serving as legal counsel to W. L. Gore & Associates. Piper Sandler is acting
More news about: W. L. GORE & ASSOCIATES
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Kelun-Biotech
Dec 17, 2025, 11:00 ET Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes
targeting—one of the broadest breast cancer pipelines.Primary markets served: US, EU5, Japan, China.Merck & Co., Inc. (MSD)Key Breast Cancer Products: Keytruda (pembrolizumab)Core strengths: Immuno-oncology leadership; strong combination
More news about: DataM Intelligence 4 Market Research LLP
Dec 17, 2025, 06:45 ET PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).Astellas Cautionary NotesIn this press release, statements made with respect to current
More news about: Astellas Pharma Inc.
Dec 16, 2025, 09:00 ET Forward Networks Named Outperformer in the 2025 GigaOm Radar for Network Validation for the Fourth Consecutive Year
transformation. Founded in 2013 by four Stanford Ph.D.s, Forward Networks is headquartered in Santa Clara, California, and backed by leading investors including MSD Partners, Goldman Sachs, Andreessen Horowitz, Threshold Ventures, Section 32, Omega Venture Partners, and A. Capital. For more information, visit
More news about: Forward Networks, Inc.
Dec 15, 2025, 10:00 ET Three-Quarters of Employers Improve Workplace Safety Scores Over Three Years
those factorsThree-quarters are engaging with MSD prevention technology, though one-quarter report limited knowledge of available solutionsThe MSD Solutions Index is part of the MSD Pledge, a global initiative launched by the MSD Solutions Lab in 2022 to unite organizations in reducing
More news about: National Safety Council
Dec 09, 2025, 13:09 ET Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.The multi-center Phase 1/2 clinical
More news about: Phanes Therapeutics, Inc.
Dec 09, 2025, 07:45 ET From Research to Measurable Patient Outcomes, Bio-IT World Conference & Expo Celebrates 25th Annual Event Advancing the Future of Precision Medicine
Presenters and participants from Novo Nordisk, MSD Czech Republic, Mayo Clinic, Polish Academy of Sciences, NVIDIA, Takeda, Vinkaya Mission's Research Foundation, India and more will gather to exchange
More news about: Cambridge Healthtech Institute
Dec 03, 2025, 10:19 ET TOC-23 Launches to Redefine the Ultra-High-Net Worth Client Experience
OfficerBramalea Partners, TortoiseEcofin, Fidelity Investments, U.S. ArmyChris Workman, CFA® – Chief Investment OfficerKKR, MSD Capital, Goldman Sachs, U.S. ArmyPhil Ierardi – Chief Operating OfficerEton Solutions, Fidelity InvestmentsHunter Steadley,
More news about: The Oglethorpe Collective, LLC (TOC-23)
Dec 03, 2025, 09:00 ET Oryx Dental Deepens Bench of Operational and Industry Experts with Appointment of New Team Members
and our decision to expand the leadership team reflects our commitment to growing and scaling responsibly without compromise," said Rania Saleh, DDS, MSD, Oryx's Founder and CEO. "Tahlor, Karen, Bryce, and Mary all bring deep operational experience that pairs perfectly with Oryx's clinical roots and dental
More news about: Oryx Dental
Dec 03, 2025, 03:00 ET FORGE HOLIDAY GROUP SELECTS GUESTY AS NEW CHANNEL MANAGER TO BOOST CUSTOMER REACH AND DISTRIBUTION
Booking.com, Expedia, Tripadvisor, Hopper, Google Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Funds, MSD Partners, Sixth Street Growth, Viola Growth, Flashpoint, and Vertex Ventures, Guesty's global team of 800+ employees across 16 offices is building the
More news about: Guesty
Dec 02, 2025, 12:30 ET Guesty Unveils First AI Agent for Revenue Management as It Accelerates Multi-Agent AI Product Strategy
Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Fund, Inovia Capital, DFO Management (formerly MSD Capital), Sixth Street Growth, Viola Growth, and Flashpoint, Guesty's global team is building the future of the short-term rental industry under one
More news about: Guesty
Dec 01, 2025, 11:25 ET APPLE PAY TO ATMS, FASHION TO FITNESS, AND GIFT IDEAS FOR EVERYONE, (RED) SOLVES HOLIDAY SHOPPING FOR THE SEASON
The (RED) Holiday Edit Vol. III, is generously supported by Merck (known as MSD outside the U.S. and Canada), and continues through the holiday season. From Bank of America's ATM network turning (RED), to great products for everyone,
More news about: (RED)
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 25, 2025, 09:00 ET Forward Networks Appoints Bobby Condon as Chief Revenue Officer to Accelerate Global Adoption of Transformational Network Digital Twin Technology
transformation. Founded in 2013 by four Stanford Ph.D.s, Forward Networks is headquartered in Santa Clara, California, and backed by leading investors including MSD Partners, Goldman Sachs, Andreessen Horowitz, Threshold Ventures, Section 32, Omega Venture Partners, and A. Capital. For more information, visit
More news about: Forward Networks, Inc.
Nov 24, 2025, 12:00 ET Merck Manuals Answers Common Questions About Age-Related Macular Degeneration
MerckManuals.com.About The Merck Manuals and MSD ManualsFirst published in 1899 as a pocket-sized reference for physicians and pharmacists, The Merck Manual has evolved into one of the
More news about: The Merck Manuals